{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T06:06:22Z","timestamp":1783922782489,"version":"3.55.0"},"reference-count":153,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100004846","name":"Beijing University of Chinese Medicine","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004846","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Ageing Research Reviews"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.arr.2026.103216","type":"journal-article","created":{"date-parts":[[2026,6,24]],"date-time":"2026-06-24T15:23:32Z","timestamp":1782314612000},"page":"103216","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Comparative efficacy and safety of pathway-targeted pharmacotherapies for Alzheimer\u2019s disease: A systematic review and network meta-analysis of phase III trials"],"prefix":"10.1016","volume":"120","author":[{"given":"Yucen","family":"Wu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yiming","family":"Di","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huixin","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liyuan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junchao","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yong","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5677-2382","authenticated-orcid":false,"given":"Diyang","family":"Lyu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.arr.2026.103216_bib1","doi-asserted-by":"crossref","DOI":"10.1093\/braincomms\/fcaf089","article-title":"Association between amyloid-\u03b242 levels and neuropsychiatric symptoms in Alzheimer\u2019s disease trials","volume":"7","author":"Abanto","year":"2025","journal-title":"Brain Commun."},{"key":"10.1016\/j.arr.2026.103216_bib2","doi-asserted-by":"crossref","first-page":"1455","DOI":"10.1007\/s40265-025-02250-5","article-title":"Clinical efficacy, safety and imaging effects of oral valiltramiprosate in APOE\u03b54\/\u03b54 homozygotes with early Alzheimer\u2019s disease: results of the phase III, randomized, double-blind, placebo-controlled, 78-week APOLLOE4 trial","volume":"85","author":"Abushakra","year":"2025","journal-title":"Drugs"},{"key":"10.1016\/j.arr.2026.103216_bib3","doi-asserted-by":"crossref","DOI":"10.1186\/s13195-026-02077-6","article-title":"Longitudinal plasma p-tau217 as a marker for tracking progression and predicting cognitive decline in Alzheimer\u2019s disease","author":"Ahn","year":"2026","journal-title":"Alzheimers Res. Ther."},{"key":"10.1016\/j.arr.2026.103216_bib4","doi-asserted-by":"crossref","first-page":"146","DOI":"10.14283\/jpad.2020.24","article-title":"The future of anti-amyloid trials","volume":"7","author":"Aisen","year":"2020","journal-title":"J. Prev. Alzheimers Dis."},{"key":"10.1016\/j.arr.2026.103216_bib5","doi-asserted-by":"crossref","DOI":"10.1212\/WNL.54.3.588","article-title":"A randomized controlled trial of prednisone in Alzheimer\u2019s disease","volume":"54","author":"Aisen","year":"2000","journal-title":"Neurology"},{"key":"10.1016\/j.arr.2026.103216_bib6","doi-asserted-by":"crossref","first-page":"102","DOI":"10.5114\/aoms.2011.20612","article-title":"Tramiprosate in mild-to-moderate Alzheimer\u2019s disease \u2013 a randomized, double-blind, placebo-controlled, multi-centre study (the alphase study)","volume":"7","author":"Aisen","year":"2011","journal-title":"Arch. Med. Sci."},{"key":"10.1016\/j.arr.2026.103216_bib7","doi-asserted-by":"crossref","first-page":"2819","DOI":"10.1001\/jama.289.21.2819","article-title":"Effects of rofecoxib or naproxen vs placebo on Alzheimer disease progression: a randomized controlled trial","volume":"289","author":"Aisen","year":"2003","journal-title":"JAMA"},{"key":"10.1016\/j.arr.2026.103216_bib8","doi-asserted-by":"crossref","first-page":"1774","DOI":"10.1001\/jama.300.15.1774","article-title":"High-dose B vitamin supplementation and cognitive decline in Alzheimer disease: A randomized controlled trial","volume":"300","author":"Aisen","year":"2008","journal-title":"JAMA"},{"key":"10.1016\/j.arr.2026.103216_bib9","doi-asserted-by":"crossref","DOI":"10.3389\/fnagi.2016.00256","article-title":"Effect of probiotic supplementation on cognitive function and metabolic status in Alzheimer\u2019s disease: a randomized, double-blind and controlled trial","volume":"8","author":"Akbari","year":"2016","journal-title":"Front. Aging Neurosci."},{"key":"10.1016\/j.arr.2026.103216_bib10","doi-asserted-by":"crossref","first-page":"1631","DOI":"10.1007\/s12035-024-04333-y","article-title":"An expanded narrative review of neurotransmitters on Alzheimer\u2019s disease: the role of therapeutic interventions on neurotransmission","volume":"62","author":"Akyuz","year":"2025","journal-title":"Mol. Neurobiol."},{"key":"10.1016\/j.arr.2026.103216_bib11","doi-asserted-by":"crossref","first-page":"e2114","DOI":"10.1212\/WNL.0000000000207156","article-title":"Accelerated brain volume loss caused by anti\u2013\u03b2-amyloid drugs: a systematic review and meta-analysis","volume":"100","author":"Alves","year":"2023","journal-title":"Neurology"},{"key":"10.1016\/j.arr.2026.103216_bib12","first-page":"27","article-title":"Therapeutics of Alzheimer\u2019s disease: past, present and future","volume":"76","author":"Anand","year":"2014","journal-title":"Neuropharmacol. Synaptic Basis Neurodegener. Disord."},{"key":"10.1016\/j.arr.2026.103216_bib13","doi-asserted-by":"crossref","DOI":"10.1016\/j.lfs.2022.120861","article-title":"Alzheimer\u2019s disease failed clinical trials","volume":"306","author":"Asher","year":"2022","journal-title":"Life Sci."},{"key":"10.1016\/j.arr.2026.103216_bib14","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1001\/jamaneurol.2023.5319","article-title":"Diagnostic accuracy of a plasma phosphorylated tau 217 immunoassay for Alzheimer disease pathology","volume":"81","author":"Ashton","year":"2024","journal-title":"JAMA Neurol."},{"key":"10.1016\/j.arr.2026.103216_bib15","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1001\/jama.2017.20373","article-title":"Effect of idalopirdine as adjunct to cholinesterase inhibitors on change in cognition in patients with Alzheimer disease: three randomized clinical trials","volume":"319","author":"Atri","year":"2018","journal-title":"JAMA"},{"key":"10.1016\/j.arr.2026.103216_bib16","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/j.jphys.2018.02.014","article-title":"Research note: comparing interventions with network meta-analysis","volume":"64","author":"Bagg","year":"2018","journal-title":"J. Physiother."},{"key":"10.1016\/j.arr.2026.103216_bib17","doi-asserted-by":"crossref","first-page":"1","DOI":"10.18637\/jss.v106.i02","article-title":"netmeta: an R package for network meta-analysis using frequentist methods","volume":"106","author":"Balduzzi","year":"2023","journal-title":"J. Stat. Softw."},{"key":"10.1016\/j.arr.2026.103216_bib18","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1126\/science.7046051","article-title":"The cholinergic hypothesis of geriatric memory dysfunction","volume":"217","author":"Bartus","year":"1982","journal-title":"Science"},{"key":"10.1016\/j.arr.2026.103216_bib19","doi-asserted-by":"crossref","first-page":"1862","DOI":"10.1056\/NEJMoa2304430","article-title":"Two phase 3 trials of gantenerumab in early Alzheimer\u2019s disease","volume":"389","author":"Bateman","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.arr.2026.103216_bib20","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.2307\/2533446","article-title":"Operating characteristics of a rank correlation test for publication bias","volume":"50","author":"Begg","year":"1994","journal-title":"Biometrics"},{"key":"10.1016\/j.arr.2026.103216_bib21","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1093\/ijnp\/pyx012","article-title":"Discontinuation, efficacy, and safety of cholinesterase inhibitors for Alzheimer\u2019s disease: a meta-analysis and meta-regression of 43 randomized clinical trials enrolling 16 106 patients","volume":"20","author":"Blanco-Silvente","year":"2017","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"10.1016\/j.arr.2026.103216_bib22","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1159\/000086613","article-title":"Galantamine prolonged-release formulation in the treatment of mild to moderate Alzheimer\u2019s disease","volume":"20","author":"Brodaty","year":"2005","journal-title":"Dement. Geriatr. Cogn. Disord."},{"key":"10.1016\/j.arr.2026.103216_bib23","doi-asserted-by":"crossref","first-page":"197","DOI":"10.14283\/jpad.2022.30","article-title":"Two randomized phase 3 studies of aducanumab in early Alzheimer\u2019s disease","volume":"9","author":"Budd Haeberlein","year":"2022","journal-title":"J. Prev. Alzheimers Dis."},{"key":"10.1016\/j.arr.2026.103216_bib24","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/S1474-4422(08)70261-8","article-title":"Safety and efficacy of galantamine (Reminyl) in severe Alzheimer\u2019s disease (the SERAD study): a randomised, placebo-controlled, double-blind trial","volume":"8","author":"Burns","year":"2009","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.arr.2026.103216_bib25","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.neuroscience.2024.11.029","article-title":"Comparison of the efficacy of updated drugs for the treatment on the improvement of cognitive function in patients with Alzheimer \u2019s disease: a systematic review and network meta- analysis","volume":"565","author":"Cao","year":"2025","journal-title":"Neuroscience"},{"key":"10.1016\/j.arr.2026.103216_bib26","doi-asserted-by":"crossref","first-page":"5025","DOI":"10.1038\/s41380-023-02140-w","article-title":"The GABAergic system in Alzheimer\u2019s disease: a systematic review with meta-analysis","volume":"28","author":"Carello-Collar","year":"2023","journal-title":"Mol. Psychiatry"},{"key":"10.1016\/j.arr.2026.103216_bib27","doi-asserted-by":"crossref","DOI":"10.1186\/s40035-023-00369-7","article-title":"Clinical evidence of human pathogens implicated in Alzheimer\u2019s disease pathology and the therapeutic efficacy of antimicrobials: an overview","volume":"12","author":"Catumbela","year":"2023","journal-title":"Transl. Neurodegener."},{"key":"10.1016\/j.arr.2026.103216_bib28","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.neulet.2019.03.050","article-title":"Serotonergic system, cognition, and BPSD in Alzheimer\u2019s disease","volume":"704","author":"Chakraborty","year":"2019","journal-title":"Neurosci. Lett."},{"key":"10.1016\/j.arr.2026.103216_bib29","doi-asserted-by":"crossref","first-page":"E1534","DOI":"10.1016\/S2214-109X(24)00264-X","article-title":"The global macroeconomic burden of Alzheimer\u2019s disease and other dementias: estimates and projections for 152 countries or territories","volume":"12","author":"Chen","year":"2024","journal-title":"Lancet Glob. Health"},{"key":"10.1016\/j.arr.2026.103216_bib30","article-title":"Evaluating the efficacy and safety of Alzheimer\u2019s disease drugs: a meta-analysis and systematic review","volume":"103","author":"Chen","year":"2024","journal-title":"Med. (Baltim. )"},{"key":"10.1016\/j.arr.2026.103216_bib31","doi-asserted-by":"crossref","DOI":"10.1186\/s12916-021-02166-3","article-title":"ROB-MEN: a tool to assess risk of bias due to missing evidence in network meta-analysis","volume":"19","author":"Chiocchia","year":"2021","journal-title":"BMC Med."},{"key":"10.1016\/j.arr.2026.103216_bib32","unstructured":"ClinicalTrials.gov, 2009. A multicenter, randomized, double-blind, placebo-controlled, phase II study of the efficacy and safety of SGS742 in subjects with mild-to-moderate Alzheimer\u2019s disease (Clinical trial registration No. NCT00093951). \u3008https:\/\/clinicaltrials.gov\/study\/NCT00093951\u3009 (accessed 24 August 2025)."},{"key":"10.1016\/j.arr.2026.103216_bib33","unstructured":"ClinicalTrials.gov, 2014a. Placebo-controlled confirmatory study of galantamine (R113675) for Alzheimer\u2019s type dementia (Clinical trial registration No. NCT00814801). \u3008https:\/\/clinicaltrials.gov\/study\/NCT00814801\u3009 (accessed 24 August 2025)."},{"key":"10.1016\/j.arr.2026.103216_bib34","unstructured":"ClinicalTrials.gov, 2014b. A 24-week, multicenter, randomized, double-blind, placebo-controlled, parallel-group, dose-finding evaluation of the efficacy, safety, and tolerability of the once-daily rivastigmine transdermal patch in patients with probable Alzheimer\u2019s disease (MMSE 10\u201320) (Clinical trial registration No. NCT00423085). \u3008https:\/\/clinicaltrials.gov\/study\/NCT00423085\u3009 (accessed 24 August 2025)."},{"key":"10.1016\/j.arr.2026.103216_bib35","unstructured":"ClinicalTrials.gov, 2015. Effect of LY450139, a \u03b3-secretase inhibitor, on the progression of Alzheimer\u2019s disease as compared with placebo (Clinical trial registration No. NCT00762411). \u3008https:\/\/clinicaltrials.gov\/study\/NCT00762411\u3009 (accessed 24 August 2025)."},{"key":"10.1016\/j.arr.2026.103216_bib36","unstructured":"ClinicalTrials.gov, 2016. CONCERT: a phase 3 multicenter, randomized, placebo-controlled, double-blind, 12-month safety and efficacy study evaluating dimebon in patients with mild-to-moderate Alzheimer\u2019s disease on donepezil (Clinical trial registration No. NCT00829374). \u3008https:\/\/clinicaltrials.gov\/study\/NCT00829374\u3009 (accessed 24 August 2025)."},{"key":"10.1016\/j.arr.2026.103216_bib37","unstructured":"ClinicalTrials.gov, 2018. A phase 3, multi-center, randomized, double-blind, placebo-controlled study to evaluate the safety and tolerability of dimebon (PF-01913539) for up to 26 weeks in patients with mild-to-moderate Alzheimer\u2019s disease (Clinical trial registration No. NCT00838110). \u3008https:\/\/clinicaltrials.gov\/study\/NCT00838110\u3009 (accessed 24 August 2025)."},{"key":"10.1016\/j.arr.2026.103216_bib38","unstructured":"ClinicalTrials.gov, 2021a. A placebo-controlled, double-blind, parallel-group, 24-month study with an open-label extension phase to evaluate the efficacy and safety of elenbecestat (E2609) in subjects with early Alzheimer\u2019s disease (Clinical trial registration No. NCT02956486). \u3008https:\/\/clinicaltrials.gov\/study\/NCT02956486\u3009 (accessed 24 August 2025)."},{"key":"10.1016\/j.arr.2026.103216_bib39","unstructured":"ClinicalTrials.gov, 2021b. Randomized, double-blind, placebo-controlled, multi-center registration trial to evaluate the efficacy and safety of azeliragon (TTP488) in patients with mild Alzheimer\u2019s disease receiving acetylcholinesterase inhibitors and\/or memantine (Clinical trial registration No. NCT02080364). \u3008https:\/\/clinicaltrials.gov\/study\/NCT02080364\u3009 (accessed 24 August 2025)."},{"key":"10.1016\/j.arr.2026.103216_bib40","unstructured":"ClinicalTrials.gov, 2023. GAIN trial: a randomized, double-blind, placebo-controlled study of COR388 in subjects with Alzheimer\u2019s disease (Clinical trial registration No. NCT03823404). \u3008https:\/\/clinicaltrials.gov\/study\/NCT03823404\u3009 (accessed 24 August 2025)."},{"key":"10.1016\/j.arr.2026.103216_bib41","unstructured":"ClinicalTrials.gov, 2025a. A phase 3, randomized, double-blind, placebo-controlled, parallel-group, 52-week study evaluating the safety and efficacy of simufilam 100 mg tablets in subjects with mild-to-moderate Alzheimer\u2019s disease (Clinical trial registration No. NCT04994483). \u3008https:\/\/clinicaltrials.gov\/study\/NCT04994483\u3009 (accessed 24 August 2025)."},{"key":"10.1016\/j.arr.2026.103216_bib42","unstructured":"ClinicalTrials.gov, 2025b. A phase 3, randomized, double-blind, placebo-controlled, parallel-group, 76-week study evaluating the safety and efficacy of two doses of simufilam in subjects with mild-to-moderate Alzheimer\u2019s disease (Clinical trial registration No. NCT05026177). \u3008https:\/\/clinicaltrials.gov\/study\/NCT05026177\u3009 (accessed 24 August 2025)."},{"key":"10.1016\/j.arr.2026.103216_bib43","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1001\/jamaneurol.2020.1840","article-title":"Safety, efficacy, and feasibility of intranasal insulin for the treatment of mild cognitive impairment and Alzheimer disease dementia: a randomized clinical trial","volume":"77","author":"Craft","year":"2020","journal-title":"JAMA Neurol."},{"key":"10.1016\/j.arr.2026.103216_bib44","article-title":"Meaningful benefit and minimal clinically important difference (MCID) in Alzheimer\u2019s disease: open peer commentary","volume":"9","author":"Cummings","year":"2023","journal-title":"Alzheimers Dement. Transl. Res. Clin. Interv."},{"key":"10.1016\/j.arr.2026.103216_bib45","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1016\/j.trci.2016.07.001","article-title":"Alzheimer\u2019s drug-development pipeline: 2016","volume":"2","author":"Cummings","year":"2016","journal-title":"Alzheimers Dement. Transl. Res. Clin. Interv."},{"key":"10.1016\/j.arr.2026.103216_bib46","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1007\/s40265-023-01938-w","article-title":"Alzheimer\u2019s disease: novel targets and investigational drugs for disease modification","volume":"83","author":"Cummings","year":"2023","journal-title":"Drugs"},{"key":"10.1016\/j.arr.2026.103216_bib47","article-title":"Alzheimer\u2019s disease drug development pipeline: 2025","volume":"11","author":"Cummings","year":"2025","journal-title":"Alzheimers Dement. Transl. Res. Clin. Interv."},{"key":"10.1016\/j.arr.2026.103216_bib48","doi-asserted-by":"crossref","first-page":"11677","DOI":"10.3390\/ijms222111677","article-title":"Glutamate and GABA in microglia-neuron cross-talk in Alzheimer\u2019s disease","volume":"22","author":"Czapski","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.arr.2026.103216_bib49","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1136\/jnnp-2022-329136","article-title":"Cognitive and neuropsychiatric effects of noradrenergic treatment in Alzheimer\u2019s disease: systematic review and meta-analysis","volume":"93","author":"David","year":"2022","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.arr.2026.103216_bib50","article-title":"Effect of long-term pharmacological treatments on Alzheimer disease: a systematic review and network meta-analysis","volume":"103","author":"Deng","year":"2024","journal-title":"Med. (Baltim. )"},{"key":"10.1016\/j.arr.2026.103216_bib51","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1056\/NEJMoa1210951","article-title":"A phase 3 trial of semagacestat for treatment of Alzheimer\u2019s disease","volume":"369","author":"Doody","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.arr.2026.103216_bib52","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa1312889","article-title":"Phase 3 trials of solanezumab for mild-to-moderate Alzheimer\u2019s disease","volume":"370","author":"Doody","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.arr.2026.103216_bib53","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1016\/S1474-4422(14)70090-0","article-title":"Advancing research diagnostic criteria for Alzheimer\u2019s disease: the IWG-2 criteria","volume":"13","author":"Dubois","year":"2014","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.arr.2026.103216_bib54","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1186\/s13195-023-01169-x","article-title":"Masitinib for mild-to-moderate Alzheimer\u2019s disease: results from a randomized, placebo-controlled, phase 3, clinical trial","volume":"15","author":"Dubois","year":"2023","journal-title":"Alzheimers Res. Ther."},{"key":"10.1016\/j.arr.2026.103216_bib55","doi-asserted-by":"crossref","DOI":"10.1093\/braincomms\/fcaf310","article-title":"Noradrenergic therapies in neurodegenerative disease: from symptomatic to disease modifying therapy?","volume":"7","author":"Durcan","year":"2025","journal-title":"Brain Commun."},{"key":"10.1016\/j.arr.2026.103216_bib56","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1001\/jama.2013.282834","article-title":"Effect of vitamin E and memantine on functional decline in Alzheimer disease: the TEAM-AD VA cooperative randomized trial","volume":"311","author":"Dysken","year":"2014","journal-title":"JAMA"},{"key":"10.1016\/j.arr.2026.103216_bib57","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1038\/s41591-025-04106-7","article-title":"Liraglutide in mild to moderate Alzheimer\u2019s disease: a phase 2b clinical trial","volume":"32","author":"Edison","year":"2026","journal-title":"Nat. Med."},{"key":"10.1016\/j.arr.2026.103216_bib58","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1056\/NEJMoa1706441","article-title":"Randomized trial of verubecestat for mild-to-moderate Alzheimer\u2019s disease","volume":"378","author":"Egan","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.arr.2026.103216_bib59","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1056\/NEJMoa1812840","article-title":"Randomized trial of verubecestat for prodromal Alzheimer\u2019s disease","volume":"380","author":"Egan","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.arr.2026.103216_bib60","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1136\/bmj.315.7109.629","article-title":"Bias in meta-analysis detected by a simple, graphical test","volume":"315","author":"Egger","year":"1997","journal-title":"BMJ"},{"key":"10.1016\/j.arr.2026.103216_bib61","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1212\/WNL.0b013e3181d6476a","article-title":"Randomized controlled trial of atorvastatin in mild to moderate Alzheimer disease: LEADe","volume":"74","author":"Feldman","year":"2010","journal-title":"Neurology"},{"key":"10.1016\/j.arr.2026.103216_bib62","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1016\/S1474-4422(07)70109-6","article-title":"Effect of rivastigmine on delay to diagnosis of Alzheimer\u2019s disease from mild cognitive impairment: the InDDEx study","volume":"6","author":"Feldman","year":"2007","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.arr.2026.103216_bib63","doi-asserted-by":"crossref","DOI":"10.1002\/alz.70086","article-title":"Lecanemab preferentially binds to smaller aggregates present at early Alzheimer\u2019s disease","volume":"21","author":"Fertan","year":"2025","journal-title":"Alzheimers Dement."},{"key":"10.1016\/j.arr.2026.103216_bib64","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/0022-3956(75)90026-6","article-title":"\u201cMini-mental state\u201d: A practical method for grading the cognitive state of patients for the clinician","volume":"12","author":"Folstein","year":"1975","journal-title":"J. Psychiatr. Res."},{"key":"10.1016\/j.arr.2026.103216_bib65","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1016\/j.bcp.2004.07.030","article-title":"SGS742: the first GABAB receptor antagonist in clinical trials","volume":"68","author":"Froestl","year":"2004","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.arr.2026.103216_bib66","doi-asserted-by":"crossref","first-page":"2873","DOI":"10.1016\/S0140-6736(16)31275-2","article-title":"Efficacy and safety of tau-aggregation inhibitor therapy in patients with mild or moderate Alzheimer\u2019s disease: a randomised, controlled, double-blind, parallel-arm, phase 3 trial","volume":"388","author":"Gauthier","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.arr.2026.103216_bib67","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1159\/000318845","article-title":"Rosiglitazone monotherapy in mild-to-moderate Alzheimer\u2019s disease: results from a randomized, double-blind, placebo-controlled phase III study","volume":"30","author":"Gold","year":"2010","journal-title":"Dement. Geriatr. Cogn. Disord."},{"key":"10.1016\/j.arr.2026.103216_bib68","doi-asserted-by":"crossref","first-page":"2557","DOI":"10.1001\/jama.2009.1866","article-title":"Effect of tarenflurbil on cognitive decline and activities of daily living in patients with mild Alzheimer disease: A randomized controlled trial","volume":"302","author":"Green","year":"2009","journal-title":"JAMA"},{"key":"10.1016\/j.arr.2026.103216_bib69","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1007\/s40263-013-0077-7","article-title":"The safety, tolerability, and efficacy of once-daily memantine (28 mg): a multinational, randomized, double-blind, placebo-controlled trial in patients with moderate-to-severe Alzheimer\u2019s disease taking cholinesterase inhibitors","volume":"27","author":"Grossberg","year":"2013","journal-title":"CNS Drugs"},{"key":"10.1016\/j.arr.2026.103216_bib70","first-page":"391","article-title":"Effects of galantamine in a 2-year, randomized, placebo-controlled study in Alzheimer\u2019s disease","volume":"10","author":"Hager","year":"2014","journal-title":"Neuropsychiatr. Dis. Treat."},{"key":"10.1016\/j.arr.2026.103216_bib71","doi-asserted-by":"crossref","first-page":"1917","DOI":"10.1093\/brain\/awy132","article-title":"The cholinergic system in the pathophysiology and treatment of Alzheimer\u2019s disease","volume":"141","author":"Hampel","year":"2018","journal-title":"Brain"},{"key":"10.1016\/j.arr.2026.103216_bib72","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1126\/science.1566067","article-title":"Alzheimer\u2019s disease: the amyloid cascade hypothesis","volume":"256","author":"Hardy","year":"1992","journal-title":"Science"},{"key":"10.1016\/j.arr.2026.103216_bib73","doi-asserted-by":"crossref","first-page":"592","DOI":"10.2174\/156720511796391935","article-title":"Rosiglitazone does not improve cognition or global function when used as adjunctive therapy to AChE inhibitors in mild-to-moderate Alzheimers disease: two phase 3 studies","volume":"8","author":"Harrington","year":"2011","journal-title":"Curr. Alzheimer Res."},{"key":"10.1016\/j.arr.2026.103216_bib74","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1016\/j.neuropharm.2005.01.019","article-title":"GABAB receptor antagonist SGS742 improves spatial memory and reduces protein binding to the cAMP response element (CRE) in the hippocampus","volume":"48","author":"Helm","year":"2005","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.arr.2026.103216_bib75","doi-asserted-by":"crossref","first-page":"547","DOI":"10.3233\/JAD-191302","article-title":"A placebo-controlled, parallel-group, randomized clinical trial of AC-1204 in mild-to-moderate Alzheimer\u2019s disease","volume":"75","author":"Henderson","year":"2020","journal-title":"J. Alzheimers Dis."},{"key":"10.1016\/j.arr.2026.103216_bib76","doi-asserted-by":"crossref","first-page":"2198","DOI":"10.1016\/S0140-6736(24)01883-X","article-title":"Passive anti-amyloid \u03b2 immunotherapy in Alzheimer\u2019s disease\u2014opportunities and challenges","volume":"404","author":"Heneka","year":"2024","journal-title":"Lancet"},{"key":"10.1016\/j.arr.2026.103216_bib77","doi-asserted-by":"crossref","first-page":"6058","DOI":"10.1073\/pnas.0909586107","article-title":"Locus ceruleus controls Alzheimer\u2019s disease pathology by modulating microglial functions through norepinephrine","volume":"107","author":"Heneka","year":"2010","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.arr.2026.103216_bib78","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1038\/s41577-024-01104-7","article-title":"Neuroinflammation in Alzheimer disease","volume":"25","author":"Heneka","year":"2025","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.arr.2026.103216_bib79","unstructured":"24. Higgins J.P.T., Thomas J., Chandler J., Cumpston M., Li T., Page M.J., et al, editor(s). Cochrane Handbook for Systematic Reviews of Intervention version 6.5 (updated August 2024). Cochrane, 2024. Available from \u3008www.cochrane.org\/handbook\u3009."},{"key":"10.1016\/j.arr.2026.103216_bib80","doi-asserted-by":"crossref","DOI":"10.1016\/j.arr.2026.103151","article-title":"Serious side effects of Alzheimer\u2019s immunotherapy demand scrutiny","volume":"119","author":"H\u00f8ilund-Carlsen","year":"2026","journal-title":"Ageing Res. Rev."},{"key":"10.1016\/j.arr.2026.103216_bib81","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1056\/NEJMoa1705971","article-title":"Trial of solanezumab for mild dementia due to Alzheimer\u2019s disease","volume":"378","author":"Honig","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.arr.2026.103216_bib82","doi-asserted-by":"crossref","first-page":"777","DOI":"10.7326\/M14-2385","article-title":"The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: checklist and explanations","volume":"162","author":"Hutton","year":"2015","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.arr.2026.103216_bib83","doi-asserted-by":"crossref","first-page":"375","DOI":"10.2165\/00023210-200115050-00004","article-title":"Pharmacodynamic-tolerability relationships of cholinesterase inhibitors for Alzheimer\u2019s disease","volume":"15","author":"Imbimbo","year":"2001","journal-title":"CNS Drugs"},{"key":"10.1016\/j.arr.2026.103216_bib84","doi-asserted-by":"crossref","first-page":"2121","DOI":"10.1038\/s41591-024-02988-7","article-title":"Revised criteria for the diagnosis and staging of Alzheimer\u2019s disease","volume":"30","author":"Jack","year":"2024","journal-title":"Nat. Med."},{"key":"10.1016\/j.arr.2026.103216_bib85","doi-asserted-by":"crossref","first-page":"l6217","DOI":"10.1136\/bmj.l6217","article-title":"Cognitive symptoms of Alzheimer\u2019s disease: clinical management and prevention","author":"Joe","year":"2019","journal-title":"BMJ 367"},{"key":"10.1016\/j.arr.2026.103216_bib86","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1038\/emm.2006.40","article-title":"Microglia, major player in the brain inflammation: their roles in the pathogenesis of Parkinson\u2019s disease","volume":"38","author":"Kim","year":"2006","journal-title":"Exp. Mol. Med."},{"key":"10.1016\/j.arr.2026.103216_bib87","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1186\/s40035-025-00465-w","article-title":"Second-generation anti-amyloid monoclonal antibodies for Alzheimer\u2019s disease: current landscape and future perspectives","volume":"14","author":"Kim","year":"2025","journal-title":"Transl. Neurodegener."},{"key":"10.1016\/j.arr.2026.103216_bib88","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1016\/j.trci.2018.06.014","article-title":"Inflammation as a central mechanism in Alzheimer\u2019s disease","volume":"4","author":"Kinney","year":"2018","journal-title":"Alzheimers Dement. Transl. Res. Clin. Interv."},{"key":"10.1016\/j.arr.2026.103216_bib89","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1038\/s41572-021-00269-y","article-title":"Alzheimer disease","volume":"7","author":"Knopman","year":"2021","journal-title":"Nat. Rev. Dis. Prim."},{"key":"10.1016\/j.arr.2026.103216_bib90","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1002\/gps.4405","article-title":"The comparative efficacy and safety of cholinesterase inhibitors in patients with mild-to-moderate Alzheimer\u2019s disease: a Bayesian network meta-analysis","volume":"31","author":"Kobayashi","year":"2016","journal-title":"Int. J. Geriatr. Psychiatry"},{"key":"10.1016\/j.arr.2026.103216_bib91","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1186\/1471-2288-13-35","article-title":"A graphical tool for locating inconsistency in network meta-analyses","volume":"13","author":"Krahn","year":"2013","journal-title":"BMC Med. Res. Methodol."},{"key":"10.1016\/j.arr.2026.103216_bib92","article-title":"Intepirdine as adjunctive therapy to donepezil for mild-to-moderate Alzheimer\u2019s disease: A randomized, placebo-controlled, phase 3 clinical trial (MINDSET)","volume":"7","author":"Lang","year":"2021","journal-title":"Alzheimers Dement. Transl. Res. Clin. Interv."},{"key":"10.1016\/j.arr.2026.103216_bib93","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1002660","article-title":"Nilvadipine in mild to moderate Alzheimer disease: A randomised controlled trial","volume":"15","author":"Lawlor","year":"2018","journal-title":"PLoS. Med."},{"key":"10.1016\/j.arr.2026.103216_bib94","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1038\/s41582-020-00435-y","article-title":"Neuroinflammation and microglial activation in Alzheimer disease: where do we go from here?","volume":"17","author":"Leng","year":"2021","journal-title":"Nat. Rev. Neurol."},{"key":"10.1016\/j.arr.2026.103216_bib95","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1016\/S2215-0366(21)00197-8","article-title":"The need to show minimum clinically important differences in Alzheimer\u2019s disease trials","volume":"8","author":"Liu","year":"2021","journal-title":"Lancet Psychiatry"},{"key":"10.1016\/j.arr.2026.103216_bib96","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1111\/joim.12959","article-title":"Current and emerging avenues for Alzheimer\u2019s disease drug targets","volume":"286","author":"Loera-Valencia","year":"2019","journal-title":"J. Intern. Med."},{"key":"10.1016\/j.arr.2026.103216_bib97","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1186\/s13643-022-01964-x","article-title":"Effects of different kinds of anti-Alzheimer\u2019s disease drugs on cognitive improvement: protocol for a systematic review and network meta-analysis of phase III clinical trials","volume":"11","author":"Lyu","year":"2022","journal-title":"Syst. Rev."},{"key":"10.1016\/j.arr.2026.103216_bib98","doi-asserted-by":"crossref","DOI":"10.1016\/j.arr.2023.101959","article-title":"Effects of three kinds of anti-amyloid-\u03b2 drugs on clinical, biomarker, neuroimaging outcomes and safety indexes: a systematic review and meta-analysis of phase II\/III clinical trials in Alzheimer\u2019s disease","volume":"88","author":"Lyu","year":"2023","journal-title":"Ageing Res. Rev."},{"key":"10.1016\/j.arr.2026.103216_bib99","doi-asserted-by":"crossref","DOI":"10.1016\/j.tjpad.2024.100016","article-title":"Blarcamesine for the treatment of early Alzheimer\u2019s disease: results from the ANAVEX2-73-AD-004 phase IIB\/III trial","volume":"12","author":"Macfarlane","year":"2025","journal-title":"J. Prev. Alzheimers Dis."},{"key":"10.1016\/j.arr.2026.103216_bib100","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.trci.2015.06.003","article-title":"A 24-week study to evaluate the effect of rilapladib on cognition and cerebrospinal fluid biomarkers of Alzheimer\u2019s disease","volume":"1","author":"Maher-Edwards","year":"2015","journal-title":"Alzheimers Dement. Transl. Res. Clin. Interv."},{"key":"10.1016\/j.arr.2026.103216_bib101","doi-asserted-by":"crossref","first-page":"1567","DOI":"10.1007\/s00228-022-03363-6","article-title":"Pharmacotherapy of Alzheimer\u2019s disease: an overview of systematic reviews","volume":"78","author":"Majidazar","year":"2022","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"10.1016\/j.arr.2026.103216_bib102","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1017\/S1041610218002156","article-title":"Efficacy and safety of idalopirdine for Alzheimer\u2019s disease: a systematic review and meta-analysis","volume":"31","author":"Matsunaga","year":"2019","journal-title":"Int. Psychogeriatr."},{"key":"10.1016\/j.arr.2026.103216_bib103","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1212\/WNL.34.7.939","article-title":"Clinical diagnosis of Alzheimer\u2019s disease: report of the NINCDS-ADRDA work group* under the auspices of department of health and human services task force on Alzheimer\u2019s disease","volume":"34","author":"McKhann","year":"1984","journal-title":"Neurology"},{"key":"10.1016\/j.arr.2026.103216_bib104","doi-asserted-by":"crossref","first-page":"2412","DOI":"10.1212\/WNL.43.11.2412-a","article-title":"The clinical dementia rating (CDR): current version and scoring rules","volume":"43","author":"Morris","year":"1993","journal-title":"Neurology"},{"key":"10.1016\/j.arr.2026.103216_bib105","doi-asserted-by":"crossref","DOI":"10.1016\/j.arr.2025.102843","article-title":"Gut-brain relationship in dementia and Alzheimer\u2019s disease: impact on stress and immunity","volume":"111","author":"Mukherjee","year":"2025","journal-title":"Ageing Res. Rev."},{"key":"10.1016\/j.arr.2026.103216_bib106","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1517\/14656566.2014.902446","article-title":"Efficacy and safety of memantine in patients with moderate-to-severe Alzheimer\u2019s disease: results of a pooled analysis of two randomized, double-blind, placebo-controlled trials in Japan","volume":"15","author":"Nakamura","year":"2014","journal-title":"Expert. Opin. Pharmacother."},{"key":"10.1016\/j.arr.2026.103216_bib107","doi-asserted-by":"crossref","first-page":"167","DOI":"10.3389\/fncel.2014.00167","article-title":"GABAergic neurotransmission and new strategies of neuromodulation to compensate synaptic dysfunction in early stages of Alzheimer\u2019s disease","volume":"8","author":"Nava-Mesa","year":"2014","journal-title":"Front. Cell. Neurosci."},{"key":"10.1016\/j.arr.2026.103216_bib108","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1038\/s41583-020-00381-0","article-title":"Gut microbial molecules in behavioural and neurodegenerative conditions","volume":"21","author":"Needham","year":"2020","journal-title":"Nat. Rev. Neurosci."},{"key":"10.1016\/j.arr.2026.103216_bib109","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1003082","article-title":"CINeMA: an approach for assessing confidence in the results of a network meta-analysis","volume":"17","author":"Nikolakopoulou","year":"2020","journal-title":"PLoS. Med."},{"key":"10.1016\/j.arr.2026.103216_bib110","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1001\/jamaneurol.2022.2909","article-title":"Evaluating the safety and efficacy of crenezumab vs placebo in adults with early Alzheimer disease: two phase 3 randomized placebo-controlled trials","volume":"79","author":"Ostrowitzki","year":"2022","journal-title":"JAMA Neurol."},{"key":"10.1016\/j.arr.2026.103216_bib111","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1186\/s13195-017-0318-y","article-title":"A phase III randomized trial of gantenerumab in prodromal Alzheimer\u2019s disease","volume":"9","author":"Ostrowitzki","year":"2017","journal-title":"Alzheimers Res. Ther."},{"key":"10.1016\/j.arr.2026.103216_bib112","doi-asserted-by":"crossref","DOI":"10.1016\/j.arr.2019.100948","article-title":"Do anti-amyloid-\u03b2 drugs affect neuropsychiatric status in Alzheimer\u2019s disease patients?","volume":"55","author":"Panza","year":"2019","journal-title":"Ageing Res. Rev."},{"key":"10.1016\/j.arr.2026.103216_bib113","article-title":"CINeMA: software for semiautomated assessment of the confidence in the results of network meta-analysis","volume":"16","author":"Papakonstantinou","year":"2020","journal-title":"Campbell Syst. Rev."},{"key":"10.1016\/j.arr.2026.103216_bib114","doi-asserted-by":"crossref","first-page":"1903","DOI":"10.1001\/jama.2010.1510","article-title":"Docosahexaenoic acid supplementation and cognitive decline in Alzheimer disease: a randomized trial","volume":"304","author":"Quinn","year":"2010","journal-title":"JAMA"},{"key":"10.1016\/j.arr.2026.103216_bib115","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1007\/s40265-014-0217-5","article-title":"Serotonergic therapies for cognitive symptoms in Alzheimer\u2019s disease: rationale and current status","volume":"74","author":"Ramirez","year":"2014","journal-title":"Drugs"},{"key":"10.1016\/j.arr.2026.103216_bib116","doi-asserted-by":"crossref","first-page":"2261","DOI":"10.1212\/WNL.54.12.2261","article-title":"Galantamine in AD: a 6-month randomized, placebo-controlled trial with a 6-month extension","volume":"54","author":"Raskind","year":"2000","journal-title":"Neurology"},{"key":"10.1016\/j.arr.2026.103216_bib117","doi-asserted-by":"crossref","DOI":"10.3389\/fnins.2025.1516746","article-title":"An exploratory analysis of bezisterim treatment associated with decreased biological age acceleration, and improved clinical measure and biomarker changes in mild-to-moderate probable Alzheimer\u2019s disease","volume":"19","author":"Reading","year":"2025","journal-title":"Front. Neurosci."},{"key":"10.1016\/j.arr.2026.103216_bib118","doi-asserted-by":"crossref","first-page":"1768","DOI":"10.1212\/WNL.0000000000003904","article-title":"A phase 3 trial of IV immunoglobulin for Alzheimer disease","volume":"88","author":"Relkin","year":"2017","journal-title":"Neurology"},{"key":"10.1016\/j.arr.2026.103216_bib119","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1017\/S031716710002148X","article-title":"A randomized, controlled trial of linopirdine in the treatment of Alzheimer\u2019s disease","volume":"24","author":"Rockwood","year":"1997","journal-title":"Can. J. Neurol. Sci."},{"key":"10.1016\/j.arr.2026.103216_bib120","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1136\/jnnp.71.5.589","article-title":"Effects of a flexible galantamine dose in Alzheimer\u2019s disease: A randomised, controlled trial","volume":"71","author":"Rockwood","year":"2001","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.arr.2026.103216_bib121","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1001\/archinte.158.9.1021","article-title":"Donepezil improves cognition and global function in Alzheimer disease: A 15-week, double-blind, placebo-controlled study. Donepezil study group","volume":"158","author":"Rogers","year":"1998","journal-title":"Arch. Intern. Med."},{"key":"10.1016\/j.arr.2026.103216_bib122","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1212\/WNL.50.1.136","article-title":"A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer\u2019s disease","volume":"50","author":"Rogers","year":"1998","journal-title":"Neurology"},{"key":"10.1016\/j.arr.2026.103216_bib123","doi-asserted-by":"crossref","first-page":"1356","DOI":"10.1176\/ajp.141.11.1356","article-title":"A new rating scale for Alzheimer\u2019s disease","volume":"141","author":"Rosen","year":"1984","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.arr.2026.103216_bib124","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1186\/s12874-015-0060-8","article-title":"Ranking treatments in frequentist network meta-analysis works without resampling methods","volume":"15","author":"R\u00fccker","year":"2015","journal-title":"BMC Med. Res. Methodol."},{"key":"10.1016\/j.arr.2026.103216_bib125","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1056\/NEJMoa1304839","article-title":"Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer\u2019s disease","volume":"370","author":"Salloway","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.arr.2026.103216_bib126","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1212\/WNL.0b013e318228bf11","article-title":"A randomized, double-blind, placebo-controlled trial of simvastatin to treat Alzheimer disease","volume":"77","author":"Sano","year":"2011","journal-title":"Neurology"},{"key":"10.1016\/j.arr.2026.103216_bib127","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1016\/S0140-6736(20)32205-4","article-title":"Alzheimer\u2019s disease","volume":"397","author":"Scheltens","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.arr.2026.103216_bib128","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1111\/joim.12191","article-title":"Clinical trials and late-stage drug development for Alzheimer\u2019s disease: an appraisal from 1984 to 2014","volume":"275","author":"Schneider","year":"2014","journal-title":"J. Intern. Med."},{"key":"10.1016\/j.arr.2026.103216_bib129","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1001\/jama.2023.13239","article-title":"Donanemab in early symptomatic Alzheimer disease: the TRAILBLAZER-ALZ 2 randomized clinical trial","volume":"330","author":"Sims","year":"2023","journal-title":"JAMA"},{"key":"10.1016\/j.arr.2026.103216_bib130","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1016\/j.jconrel.2024.01.047","article-title":"Alzheimer\u2019s disease current therapies, novel drug delivery systems and future directions for better disease management","volume":"367","author":"Singh","year":"2024","journal-title":"J. Control. Release"},{"key":"10.1016\/j.arr.2026.103216_bib131","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1186\/s13195-023-01356-w","article-title":"NeuroEPO plus (NeuralCIM\u00ae) in mild-to-moderate Alzheimer\u2019s clinical syndrome: the ATHENEA randomized clinical trial","volume":"15","author":"Sosa","year":"2023","journal-title":"Alzheimers Res. Ther."},{"key":"10.1016\/j.arr.2026.103216_bib132","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1056\/NEJMoa2305032","article-title":"Trial of solanezumab in preclinical Alzheimer\u2019s disease","volume":"389","author":"Sperling","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.arr.2026.103216_bib133","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1001\/jamaneurol.2020.4857","article-title":"Findings of efficacy, safety, and biomarker outcomes of atabecestat in preclinical Alzheimer disease: a truncated randomized phase 2b\/3 clinical trial","volume":"78","author":"Sperling","year":"2021","journal-title":"JAMA Neurol."},{"key":"10.1016\/j.arr.2026.103216_bib134","doi-asserted-by":"crossref","first-page":"l4898","DOI":"10.1136\/bmj.l4898","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","author":"Sterne","year":"2019","journal-title":"BMJ 366"},{"key":"10.1016\/j.arr.2026.103216_bib135","doi-asserted-by":"crossref","first-page":"2693","DOI":"10.1002\/(SICI)1097-0258(19991030)18:20<2693::AID-SIM235>3.0.CO;2-V","article-title":"Explaining heterogeneity in meta-analysis: a comparison of methods","volume":"18","author":"Thompson","year":"1999","journal-title":"Stat. Med."},{"key":"10.1016\/j.arr.2026.103216_bib136","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1004568","article-title":"Efficacy and safety of passive immunotherapies targeting amyloid beta in Alzheimer\u2019s disease: a systematic review and meta-analysis","volume":"22","author":"Tonegawa-Kuji","year":"2025","journal-title":"PLoS. Med."},{"key":"10.1016\/j.arr.2026.103216_bib137","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1111\/jgs.15069","article-title":"Comparative effectiveness and safety of cognitive enhancers for treating Alzheimer\u2019s disease: systematic review and network metaanalysis","volume":"66","author":"Tricco","year":"2018","journal-title":"J. Am. Geriatr. Soc."},{"key":"10.1016\/j.arr.2026.103216_bib138","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1056\/NEJMoa2212948","article-title":"Lecanemab in early Alzheimer\u2019s disease","volume":"388","author":"Van Dyck","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.arr.2026.103216_bib139","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1186\/s13195-016-0189-7","article-title":"Bapineuzumab for mild to moderate Alzheimer\u2019s disease in two global, randomized, phase 3 trials","volume":"8","author":"Vandenberghe","year":"2016","journal-title":"Alzheimers Res. Ther."},{"key":"10.1016\/j.arr.2026.103216_bib140","doi-asserted-by":"crossref","first-page":"75","DOI":"10.18773\/austprescr.2024.021","article-title":"New and emerging drug therapies for Alzheimer disease","volume":"47","author":"Waite","year":"2024","journal-title":"Aust. Prescr."},{"key":"10.1016\/j.arr.2026.103216_bib141","doi-asserted-by":"crossref","DOI":"10.1002\/hup.70017","article-title":"The efficacy and safety of amyloid beta-directed monoclonal antibodies for Alzheimer\u2019s disease: a systematic review and meta-analysis of phase III randomized controlled trials","volume":"40","author":"Wei","year":"2025","journal-title":"Hum. Psychopharmacol. - Clin. Exp."},{"key":"10.1016\/j.arr.2026.103216_bib142","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1001\/jamaneurol.2019.3988","article-title":"Efficacy and safety of lanabecestat for treatment of early and mild Alzheimer disease: the AMARANTH and DAYBREAK-ALZ randomized clinical trials","volume":"77","author":"Wessels","year":"2020","journal-title":"JAMA Neurol."},{"key":"10.1016\/j.arr.2026.103216_bib143","doi-asserted-by":"crossref","first-page":"435","DOI":"10.3233\/JAD-170560","article-title":"Potential of low dose leuco-methylthioninium bis (hydromethanesulphonate) (LMTM) monotherapy for treatment of mild Alzheimer\u2019s disease: cohort analysis as modified primary outcome in a phase III clinical trial","volume":"61","author":"Wilcock","year":"2017","journal-title":"J. Alzheimers Dis."},{"key":"10.1016\/j.arr.2026.103216_bib144","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1136\/bmj.321.7274.1445","article-title":"Efficacy and safety of galantamine in patients with mild to moderate Alzheimer\u2019s disease: multicentre randomised controlled trial","volume":"321","author":"Wilcock","year":"2000","journal-title":"BMJ"},{"key":"10.1016\/j.arr.2026.103216_bib145","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1016\/S1474-4422(14)70198-X","article-title":"Safety and efficacy of idalopirdine, a 5-HT 6 receptor antagonist, in patients with moderate Alzheimer\u2019s disease (LADDER): a randomised, double-blind, placebo-controlled phase 2 trial","volume":"13","author":"Wilkinson","year":"2014","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.arr.2026.103216_bib146","doi-asserted-by":"crossref","first-page":"S14","DOI":"10.1212\/01.wnl.0000281847.17519.e0","article-title":"IDEAL: a 6-month, double-blind, placebo-controlled study of the first skin patch for Alzheimer disease","volume":"69","author":"Winblad","year":"2007","journal-title":"Neurology"},{"key":"10.1016\/j.arr.2026.103216_bib147","doi-asserted-by":"crossref","first-page":"a006346","DOI":"10.1101\/cshperspect.a006346","article-title":"Inflammation in Alzheimer disease--a brief review of the basic science and clinical literature","volume":"2","author":"Wyss-Coray","year":"2012","journal-title":"Cold Spring Harb. Perspect. Med."},{"key":"10.1016\/j.arr.2026.103216_bib148","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1186\/s13195-021-00795-7","article-title":"A 36-week multicenter, randomized, double-blind, placebo-controlled, parallel-group, phase 3 clinical trial of sodium oligomannate for mild-to-moderate Alzheimer\u2019s dementia","volume":"13","author":"Xiao","year":"2021","journal-title":"Alzheimers Res. Ther."},{"key":"10.1016\/j.arr.2026.103216_bib149","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1038\/s41398-026-03923-9","article-title":"Evaluating the potential of acupuncture for Alzheimer\u2019s disease treatment: a meta-analysis and systematic review of mouse model studies","volume":"16","author":"Yang","year":"2026","journal-title":"Transl. Psychiatry"},{"key":"10.1016\/j.arr.2026.103216_bib150","doi-asserted-by":"crossref","DOI":"10.1016\/j.arr.2024.102595","article-title":"Disease-modifying therapies for Alzheimer\u2019s disease: Clinical trial progress and opportunity","volume":"103","author":"Zhang","year":"2025","journal-title":"Ageing Res. Rev."},{"key":"10.1016\/j.arr.2026.103216_bib151","doi-asserted-by":"crossref","DOI":"10.1080\/19490976.2023.2271613","article-title":"Gut microbiome-targeted therapies for Alzheimer\u2019s disease","volume":"15","author":"Zhang","year":"2023","journal-title":"Gut Microbes"},{"key":"10.1016\/j.arr.2026.103216_bib152","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1038\/s41392-024-01911-3","article-title":"Recent advances in Alzheimer\u2019s disease: mechanisms, clinical trials and new drug development strategies","volume":"9","author":"Zhang","year":"2024","journal-title":"Signal. Transduct. Target. Ther."},{"key":"10.1016\/j.arr.2026.103216_bib153","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1016\/j.advnut.2023.04.005","article-title":"Gut microbiota and its metabolites: bridge of dietary nutrients and Alzheimer\u2019s disease","volume":"14","author":"Zhu","year":"2023","journal-title":"Adv. Nutr."}],"container-title":["Ageing Research Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1568163726002084?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1568163726002084?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T05:17:27Z","timestamp":1783919847000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1568163726002084"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":153,"alternative-id":["S1568163726002084"],"URL":"https:\/\/doi.org\/10.1016\/j.arr.2026.103216","relation":{},"ISSN":["1568-1637"],"issn-type":[{"value":"1568-1637","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Comparative efficacy and safety of pathway-targeted pharmacotherapies for Alzheimer\u2019s disease: A systematic review and network meta-analysis of phase III trials","name":"articletitle","label":"Article Title"},{"value":"Ageing Research Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.arr.2026.103216","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"103216"}}